Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate

Journal of Cellular Biochemistry

Volumn 99, Issue 3, 2006, Pages 665-670

  Gacio, Ana Fernandez ^a,b   Fernandez Marcos, Carlos ^a,c   Swamy, Narasimha ^a   Dunn, Darra ^a   Ray, Rahul ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Breast cancer; Estrogen receptor targeted delivery of phototoxins; Photodynamic cell kill; Tamoxifen porphyrin conjugate

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PORPHYRIN; TAMOXIFEN; TAMOXIFEN PYROPHEOPHORBIDE CONJUGATE; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CELL KILLING; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CONJUGATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGHT EXPOSURE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 33749464012     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20932     Document Type: Article

References (27)

1. 6 enhances its photosensitizing activity. J Biol Chem 272:20328-20331.
2. Allison R, Mang T, Hewson G, Snider W, Dougherty TJ. 2001. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer (Phila) 91:1-8.
3. Axer-Siegel R, Ehrlich R, Yassur Y, Rosenblatt I, Kramer M, Priel E, Benjamini Y, Weinberg D. 2004. Photodynamic therapy for age-related macular degeneration in a clinical setting: Visual results and angiographic patterns. Am J Ophthalmol 137:258-264.
4. Dardes RC, O'Reagan RM, Gajdos C, Robinson SP, Bentrem D. 2002. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin Cancer Res 8:1995-2001.
5. Derycke AS, Witte PA. 2004. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 56:17-30.
6. Dolmans DEJGJ, Kadambi A, Hill JS, Flores KR, Gerber JN, Walker JP, Borel Rinkes IHM, Jain RK, Fukumura D. 2002. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 62:4289-4294.
7. Essigman JM, Rink SM, Park HJ, Croy RG. 2001. Design of DNA damaging agents that hijack transcription factors and block DNA repair. Adv Exp Med Biol 500:301-313.
8. Fisher AM, Murphree AL, Gomer CJ. 1995. Clinical and pre-clinical photodynamic therapy. Laser Surg Med 17:2-31.
9. Goff BA, Blake J, Bamberg MP, Hasan T. 1996. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer 74:1194-1198.
10. Goldenberg GJ, Froses EK. 1982. Drug and hormone sensitivity of estrogen receptor positive and negative human breast cancer cells in vitro. Cancer Res 42:5147-5151.
11. James DA, Swamy N, Hanson RN, Ray R. 1999. Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for photodynamic therapy of cancer. Bioorg Med Chem Lett 9:2379-2384.
12. Kuduk SD, Zheng FF, Sepp-Lorenzino L, Rosen N, Danishefsky SJ. 1999. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett 9:1233-1238.
13. Mang TS, Allison R, Hewson G, Snider W, Moskowitz RA. 1998. Phase II/III clinical study of tin ethyl etiopurpurin(Puryltin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am 4:378-384.
14. Marmur ES, Schmults CD, Goldberg DJ. 2004. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 30:264-271.
15. Park W-C, Jordan VC. 2002. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends Mol Med 8:82-88.
16. Peach K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. 1997. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP-1 sites. Science 277:1508-1510.
17. Purohit A, Wyatt J, Hynd G, Wright J, El-Shafey A, Swamy N, Ray R, Jones GB. 2001. Chemical synthesis of hormone receptor probes: High affinity photoactivated enediyne-estrogens. Tetrahedron Lett 42:8579-8582.
18. Sharma U, Marquis JC, Nicole Dinaut A, Hillier SM, Fedeles B, Rye PT, Essigman JM, Croy RG. 2004. Design, synthesis, and evaluation of estradiol-linked gentotoxicants as anti-cancer agents. Bioorg Med Chem Lett 14:3829-3833.
19. Sharman WM, van Lier JE, Allen CM. 2004. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56:53-76.
20. Sibata CH, Colussi VC, Oleinik NL, Kinsella TJ. 2001. Photodynamic therapy in oncology. Expert Opin Pharmacother 6:917-927.
21. Skaddan MB, Wust FR, Katzenellenbogen JA. 1999. Synthesis and binding of novel Re-containing 7-alpha-substituted estradiol complexes: Models for breast cancer imaging agents. J Org Chem 64:8108-8121.
22. Swamy N, Purohit A, Gacio Fernandez A, Jones GB, Ray R. 2001. Estrogen receptor-mediated targeted photodynamic therapy. Twenty Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, AZ, 2001.
23. Swamy N, James DA, Mohr SC, Hanson RN, Ray R. 2002. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. Bioorg Med Chem 10:3237-3243.
24. 17α-alkynylestradiol-porphyrin conjugate. J Cell Biochem (in press).
25. Vrouenraets MB, Visser GW, Stiger M, Oppelaar H, Snow GB, van Dongen GA. 2001. Targeting of aluminum (III) pthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: Improved efficacy in photodynamic therapy. Cancer Res 61:1970-1975.
26. Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ. 1992. The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol 6:157-167.
27. Yamamoto J, Hirano T, Koide M, Kohno E, Inenaga C, Tokuyama T, Yokota N, Yamamoto S, Terakawa S, Namba H. 2005. Selective accumulation and strong photodynamic effects of a new photosensitizer, ATX-S10.Na (II), in experimental malignant glioma. Int J Oncol 27:1207-1213.